ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results RAMSEY, N.J.

ADMA Biologics Provides Corporate Update

and Reports Third Quarter 2017 Financial Results

RAMSEY, N.J. - November 3, 2017 - ADMA Biologics,

Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and

specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of

Primary Immune Deficiency Disease ("PIDD") and the prevention and treatment of certain infectious immunological diseases,

today provided a corporate update, including recent progress with its manufacturing and quality systems, and announced its financial

results for the fiscal quarter ended September 30, 2017.

"Since completing the acquisition of certain assets of

Biotest Pharmaceuticals Corporation's Therapy Business Unit ("BTBU"), we are pleased to report we continue to

make progress with business integration, improving operating efficiencies, and remedying our outstanding U.S. Food and Drug Administration

("FDA") compliance issues," said Adam Grossman, President and Chief Executive Officer of ADMA.

Mr. Grossman continued, "Importantly, we remain on schedule

to be FDA inspection-ready by year-end 2017. We have continued commercial production for Nabi-HB , an FDA-approved hyperimmune

globulin for the treatment of Hepatitis B during the third quarter of 2017 and further advanced our optimization program for our

immunoglobulin manufacturing process, which is the process used for both Bivigam , an FDA-approved immune globulin intravenous

("IGIV") for the treatment of primary humoral immunodeficiency and RI-002 our lead IGIV product candidate intended

for immunodeficient patients. We are pleased with our operational progress, as we achieved year-over-year revenue growth of approximately

61 percent in the third quarter ," concluded Mr. Grossman.

2017 YTD Achievements and Anticipated Goals

Completed the acquisition of the BTBU, creating a U.S.-domiciled, vertically-integrated

commercial drug manufacturer and provider of specialty- plasma biotherapeutics

Generated accretive revenues from FDA-approved BTBU-acquired assets

Continued the successful integration of BTBU operations into ADMA

Established a timeline and engaged Subject Matter Experts to assist with the remediation

of the FDA warning letter and compliance issues for the acquired Boca Raton, FL manufacturing facility (the "Boca Facility")

Resumed commercial product manufacturing at the Boca Facility

On track to be FDA "Inspection-Ready" by year-end 2017

Initiated the buildout of our third ADMA BioCenter plasma collection facility

Secured a second patent for immunotherapeutics methods for RI-002

Financial Results for the Three Months Ended September 30,

ADMA reported total revenues of $4.7 million for the third quarter

ended September 30, 2017, as compared to $2.9 million for the third quarter ended September 30, 2016, representing an increase

of approximately 61%. This growth was primarily attributable to sales of Nabi-HB as a result of the acquisition of certain

BTBU assets, which included the commercial rights to Nabi-HB .

The consolidated net loss for the quarter ended September 30,

2017 was $15.2 million, or $0.59 per basic and diluted share, as compared to a consolidated net loss of $4.3 million, or $0.34

per basic and diluted share, for the quarter ended September 30, 2016. The increase in net loss of $10.9 million was primarily

attributable to increased product revenue costs of $9.6 million, which included manufacturing costs related to the Boca Facility,

including third-party consultant fees of approximately $2.0 million pertaining to the remediation efforts in response to the FDA

warning letter. Additionally, the Company incurred increased selling, general and administrative expenses of $2.4 million, which

were primarily related to costs associated with the Boca Facility. These costs were partially offset by increased revenues of $1.8

million. Included in the net loss for the third quarter ended September 30, 2017 were non-cash expenses of $1.9 million for stock-based

compensation, non-cash interest expense and depreciation and amortization.

Financial Results for the Nine Months Ended September 30,

ADMA reported total revenues of $10.8 million for the nine months

ended September 30, 2017, as compared to $7.3 million for the nine months ended September 30, 2016, representing a period-over-period

increase of approximately 47%, which was driven by the sales of Nabi-HB and increased plasma collection revenues.

The consolidated net loss for the nine months ended September

30, 2017 was $30.8 million, or $1.67 per basic and diluted share, as compared to a consolidated net loss of $15.0 million, or $1.26

per basic and diluted share, for the nine months ended September 30, 2016. The increase in net loss of $15.8 million was primarily

attributable to increased product revenue costs of $12.9 million, which include manufacturing costs related to the Boca Facility,

including third-party consultant fees of approximately $2.5 million pertaining to the remediation efforts in response to the FDA

warning letter, as well as increased selling, general and administrative expenses of $7.7 million, which include transaction costs

for the acquisition of the BTBU of $3.9 million. These costs were partially offset by increased revenues of $3.5 million for the

quarter ended September 30, 2017. Included in the net loss for the nine months ended September 30, 2017 were non-cash expenses

of $2.8 million for stock-based compensation, depreciation and amortization and non-cash interest expense.

At September 30, 2017, ADMA had cash, cash equivalents and short-term

investments of $13.6 million, as compared to $15.3 million at December 31, 2016. ADMA's net working capital as of September

30, 2017 was $18.1 million, as compared to $10.4 million as of December 31, 2016.

About ADMA Biologics, Inc. (ADMA)

ADMA is a vertically integrated commercial biopharmaceutical

and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment

of Primary Immune Deficiency Disease ("PIDD") and the prevention and treatment of certain infectious immunological

diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations

for the treatment and prevention of certain infectious immunological diseases. The target patient populations include immune-compromised

individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA

has received U.S. Patents 9,107,906 and 9,714,283 related to certain aspects of its product candidate, RI-002. For more information,

please visit www.admabiologics.com.

Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include,

without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and

may contain the words "estimate," "project," "intend," "forecast," "target,"

"anticipate," "plan," "planning," "expect," "believe," "will,"

"is likely," "will likely," "should," "could," "would," "may,"

or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, without

limitation, the anticipated benefits and synergies of our recent acquisition of certain assets from Biotest Pharmaceuticals Corporation

("BPC") (the "BPC Transaction"), including optimization of the combined businesses, operations and products

and services, including liquidity, debt repayment and capital return expectations, as well as the capitalization, resources and

ownership structure of the combined company, the nature, strategy and focus of the combined company and the management and governance

structure of the combined company, our plans to develop, manufacture, market, launch and expand our own commercial infrastructure

and commercialize our current products and future products and the success of such efforts, the timing and ability to conduct further

testing of RI-002 in humans if needed, the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory

approvals of our current products and product candidates, and the labeling or nature of any such approvals, the timeframe within

which we may receive approval from the U.S. Food and Drug Administration ("FDA"), if at all, of our Biologics License

Application ("BLA") for RI-002, our ability to address the outstanding issues in the FDA's Complete Response Letter

("CRL"), as well as other deficiencies existing at the manufacturing facility we acquired in the BPC Transaction and

the effect any adverse events on such manufacturing facility could have on us or our business, our ability to generate revenue,

if any, from the potential commercialization of RI-002, if approved by the FDA, the achievement of or expected timing, progress

and results of clinical development, clinical trials and potential regulatory approvals, our ability to resume the manufacturing

of Bivigam once the deficiencies identified in the CRL, and the warning letter issued by the FDA to BPC on November 25, 2014

with respect to the outstanding issues at the manufacturing facility in Boca Raton, Florida which we acquired from BPC in June

2017, have been resolved by us to the satisfaction of the FDA, as well as a positive review of the optimized manufacturing process

under a Prior Approval Supplement by the FDA our dependence upon our third-party and related party customers and vendors and their

compliance with regulatory bodies our ability to obtain adequate quantities of FDA-approved normal source plasma and Respiratory

Syncytial Virus ("RSV"), high-titer plasma with proper specifications, our plans to increase our supplies of plasma,

the potential indications for our product candidates, our ability to expand our plasma center network, regulatory processes, interpretations

of final data, possible characteristics of RI-002, acceptability of any of our products as well as RI-002 for any purpose, by physicians,

patients or payers, concurrence by the FDA with our conclusions and the satisfaction by us of its guidance, the likelihood and